Literature DB >> 21816190

Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease.

Debaditya Bhattacharya1, Mekki Bensaci, Kathryn E Luker, Gary Luker, Steven Wisdom, Sam R Telford, Linden T Hu.   

Abstract

Lyme disease is a major human health problem which continues to increase in incidence and geographic distribution. As a vector-borne zoonotic disease, Lyme disease may be amenable to reservoir targeted strategies for control. We have previously reported that a vaccinia virus (VV) based vaccine expressing outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease, protects inbred strains of laboratory mice against infection by feeding ticks and clears the ticks of infection when administered by gavage. Here we extend these studies to develop an effective bait formulation for delivery of the VV based vaccine and test its characteristics under simulated environmental conditions. We show that this vaccine is efficacious in decreasing acquisition of B. burgdorferi by uninfected larval ticks as well as in decreasing transmission from infected ticks to its natural reservoir, Peromyscus leucopus, when fed to mice in oral baits. Using live, in vivo imaging techniques, we describe the distribution of vaccinia virus infection after ingestion of the baited vaccines and establish the use of in vivo imaging technology for optimization of bait delivery. In summary, a VV based OspA vaccine is stable in an oral bait preparation and provides protection against infection for both the natural reservoir and the tick vector of Lyme disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816190      PMCID: PMC3577423          DOI: 10.1016/j.vaccine.2011.07.100

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants.

Authors:  M M Gherardi; M Esteban
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

2.  Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.

Authors:  C J Luke; R C Huebner; V Kasmiersky; A G Barbour
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

3.  Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread.

Authors:  Kathryn E Luker; Martha Hutchens; Tracey Schultz; Andrew Pekosz; Gary D Luker
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

Review 4.  The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator.

Authors:  M D Kramer; R Wallich; M M Simon
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

5.  OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks.

Authors:  A M de Silva; D Fish; T R Burkot; Y Zhang; E Fikrig
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle.

Authors:  Jean I Tsao; J Timothy Wootton; Jonas Bunikis; Maria Gabriela Luna; Durland Fish; Alan G Barbour
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

Review 7.  Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control.

Authors:  C E Rupprecht; C A Hanlon; D Slate
Journal:  Dev Biol (Basel)       Date:  2004

8.  Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species.

Authors:  B Brochier; J Blancou; I Thomas; B Languet; M Artois; M P Kieny; J P Lecocq; F Costy; P Desmettre; G Chappuis
Journal:  J Wildl Dis       Date:  1989-10       Impact factor: 1.535

9.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Authors:  A C Steere; V K Sikand; F Meurice; D L Parenti; E Fikrig; R T Schoen; J Nowakowski; C H Schmid; S Laukamp; C Buscarino; D S Krause
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

10.  OspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection.

Authors:  E Fikrig; S W Barthold; R A Flavell
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

View more
  24 in total

1.  Evidence for Personal Protective Measures to Reduce Human Contact With Blacklegged Ticks and for Environmentally Based Control Methods to Suppress Host-Seeking Blacklegged Ticks and Reduce Infection with Lyme Disease Spirochetes in Tick Vectors and Rodent Reservoirs.

Authors:  Lars Eisen; Marc C Dolan
Journal:  J Med Entomol       Date:  2016-09-01       Impact factor: 2.278

2.  Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens.

Authors:  Vanessa Cook; Alan G Barbour
Journal:  Ticks Tick Borne Dis       Date:  2015-04-28       Impact factor: 3.744

Review 3.  Borrelia burgdorferi and tick proteins supporting pathogen persistence in the vector.

Authors:  Faith Kung; Juan Anguita; Utpal Pal
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

4.  Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.

Authors:  Maarten J Voordouw; Haley Tupper; Özlem Önder; Godefroy Devevey; Christopher J Graves; Brian D Kemps; Dustin Brisson
Journal:  Vector Borne Zoonotic Dis       Date:  2013-02-21       Impact factor: 2.133

5.  Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release.

Authors:  Aurelie Kern; Chensheng W Zhou; Feng Jia; Qiaobing Xu; Linden T Hu
Journal:  Vaccine       Date:  2016-08-05       Impact factor: 3.641

6.  Live Attenuated Borrelia burgdorferi Targeted Mutants in an Infectious Strain Background Protect Mice from Challenge Infection.

Authors:  Beth L Hahn; Lavinia J Padmore; Laura C Ristow; Michael W Curtis; Jenifer Coburn
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

7.  Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference.

Authors:  Denice Spero; Lauren Levitz; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

8.  Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi.

Authors:  Mekki Bensaci; Debaditya Bhattacharya; Roger Clark; Linden T Hu
Journal:  Vaccine       Date:  2012-08-02       Impact factor: 3.641

9.  Non-anticoagulant Heparin as a Pre-exposure Prophylaxis Prevents Lyme Disease Infection.

Authors:  Yi-Pin Lin; Yanlei Yu; Ashley L Marcinkiewicz; Patricia Lederman; Thomas M Hart; Fuming Zhang; Robert J Linhardt
Journal:  ACS Infect Dis       Date:  2020-01-30       Impact factor: 5.084

Review 10.  Infection resistance and tolerance in Peromyscus spp., natural reservoirs of microbes that are virulent for humans.

Authors:  Alan G Barbour
Journal:  Semin Cell Dev Biol       Date:  2016-07-02       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.